Related resources
Full-text held externally
- PMID: 26072396
- UKPMCID: 26072396
- DOI: 10.1053/j.gastro.2015.06.002
Search for item elsewhere
University researcher(s)
Academic department(s)
Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Coenen, Marieke J H; de Jong, Dirk J; van Marrewijk, Corine J; Derijks, Luc J J; Vermeulen, Sita H; Wong, Dennis R; Klungel, Olaf H; Verbeek, Andre L M; Hooymans, Piet M; Peters, Wilbert H M; Te Morsche, Rene H M; Newman, William G; Scheffer, Hans; Guchelaar, Henk-Jan; Franke, Barbara
Gastroenterology. 2015;.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 26072396
- UKPMCID: 26072396
- DOI: 10.1053/j.gastro.2015.06.002
Abstract
BACKGROUND AND AIMS: More than 20% of patients with inflammatory bowel disease (IBD) discontinue thiopurine therapy due to severe adverse drug reactions (ADRs); leucopenia is one of the most serious ADRs. Variants in the gene encoding thiopurine S-methyltransferase (TPMT) alter its enzymatic activity, resulting in higher levels of thiopurine metabolites, which can cause leucopenia. We performed a prospective study to determine whether genotype analysis of TPMT before thiopurine treatment, and dose selection based on the results, affects outcomes of patients with IBD. METHODS: In a study performed at 30 Dutch hospitals, patients were randomly assigned to groups that received standard treatment (control) or pre-treatment screening (intervention) for 3 common variants of TPMT (TPMT*2, *3A, and *3C). Patients in the intervention group found to be heterozygous carriers of a variant received 50% of the standard dose of thiopurine (azathioprine or 6-mercaptopurine), and those homozygous for a variant received 0%-10% of the standard dose. We compared, in an intention-to-treat analysis, outcomes of the intervention (n=405) and control groups (n=378) after 20 weeks of treatment. Primary outcomes were occurrence of hematologic ADRs (leukocyte count <3.0*109/L or reduced platelet count <100*109/L) and disease activity (based on the Harvey-Bradshaw Index for Crohn's disease [n=356] or partial-Mayo score for ulcerative colitis [n=253]). RESULTS: Similar proportions of patients in the intervention and control groups developed a hematologic ADR (7.4% vs 7.9%; relative risk=0.93; 95% confidence interval, 0.57-1.52) in the 20 weeks of follow-up; the groups also had similar mean levels of disease activity (P=0.18 for Crohn's disease and P=0.14 for ulcerative colitis). However, a significantly smaller proportion of carriers of the TPMT variants in the intervention group (2.6%) developed hematologic ADRs compared with those in the control group (22.9%) (relative risk, 0.11; 95% confidence interval, 0.01-0.85). CONCLUSIONS: Screening for variants in TPMT did not reduce the proportions of patients with hematological ADRs during thiopurine treatment for IBD. However, there was a 10-fold reduction in hematologic ADRs among variant carriers who were identified and received a dose reduction, compared with variant carriers who did not, without differences in treatment efficacy. ClinicalTrials.gov number: NCT00521950.